Profile: Xoma (US) LLC develops and manufactures therapeutic antibodies. Our products are xoma 052, HCD122 mab and CIMZIA®. Our xoma 052 is an anti-inflammatory agent. It is used to treat many diseases including diabetes, rheumatoid arthritis, acute gout, systemic juvenile idiopathic arthritis (sJIA) and also for the treatment of cardiovascular disease. Our HCD122 mab is a fully human anti-CD40 antibody intended as a treatment for B-cell mediated diseases, including malignancies and autoimmune diseases. The antibody has a dual mechanism of action that involves blocking tumor cell growth and survival signals while recruiting immune effector cells to kill tumor cells through a process known as antibody-dependent cellular cytotoxicity (ADCC). Our CIMZIA® is an antibody fragment that blocks tumor necrosis factor (TNF) alpha.

The company has revenues of USD 25-50 Million, has ~340 employees. NASDAQ:XOMA (SEC Filings)